Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 10;13(10):299.
doi: 10.3390/ph13100299.

The Principles, Mechanisms, and Benefits of Unconventional Agents in the Treatment of Biofilm Infection

Affiliations
Review

The Principles, Mechanisms, and Benefits of Unconventional Agents in the Treatment of Biofilm Infection

Jasminka Talapko et al. Pharmaceuticals (Basel). .

Abstract

Today, researchers are looking at new ways to treat severe infections caused by resistance to standard antibiotic therapy. This is quite challenging due to the complex and interdependent relationships involved: the cause of infection-the patient-antimicrobial agents. The sessile biofilm form is essential in research to reduce resistance to very severe infections (such as ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa, and Enterobacter spp). The purpose of this study is to elucidate the mechanisms of the occurrence, maintenance, and suppression of biofilm infections. One form of biofilm suppression is the efficient action of natural antagonists of bacteria-bacteriophages. Bacteriophages effectively penetrate the biofilm's causative cells. They infect those bacterial cells and either destroy them or prevent the infection spreading. In this process, bacteriophages are specific, relatively easy to apply, and harmless to the patient. Antimicrobial peptides (AMPs) support the mechanisms of bacteriophages' action. AMPs could also attack and destroy infectious agents on their own (even on biofilm). AMPs are simple, universal peptide molecules, mainly cationic peptides. Additional AMP research could help develop even more effective treatments of biofilm (bacteriophages, antibiotics, AMPs, nanoparticles). Here, we review recent unconventional agents, such as bacteriophages and AMPs, used for eradication of biofilm, providing an overview of potentially new biofilm treatment strategies.

Keywords: antimicrobial peptides; bacteriophage; biofilm; immunomodulatory action; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Phases of biofilm formation. The formation starts with the attachment of planktonic cells (purple), followed by binding to the surface (grey). The bacteria then form a microcolony and begin to produce an extracellular matrix (pink). In the maturation phase, the biofilm grows into a tower or mushroom-shaped structure due to the polysaccharides. Finally, some bacteria start to disperse to another site and form a new biofilm.
Figure 2
Figure 2
Bacteriophage life cycle. The bacteriophage first interacts with receptors on the host, absorbs, and then injects its genome to infect a bacterium. The lytic cycle involves the production of new bacteriophages and their release from the infected cell by lysis. The lysogenic cycle results in integrating a phage genome into the bacterial genome, which replicates in concert with the host DNA.
Figure 3
Figure 3
The mechanisms of antimicrobial peptides action.

References

    1. Hendry A.P., Kinnison M.T., Heino M., Day T., Smith T.B., Fitt G., Bergstrom C.T., Oakeshott J., Jørgensen P.S., Zalucki M.P., et al. Evolutionary principles and their practical application. Evol. Appl. 2011;4:159–183. doi: 10.1111/j.1752-4571.2010.00165.x. - DOI - PMC - PubMed
    1. Van Baarlen P., Van Belkum A., Summerbell R.C., Crous P.W., Thomma B.P.H.J. Molecular mechanisms of pathogenicity: How do pathogenic microorganisms develop cross-kingdom host jumps? FEMS Microbiol. Rev. 2007;31:239–277. doi: 10.1111/j.1574-6976.2007.00065.x. - DOI - PubMed
    1. Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog. Glob. Health. 2015;109:309–318. doi: 10.1179/2047773215Y.0000000030. - DOI - PMC - PubMed
    1. Aslam B., Wang W., Arshad M.I., Khurshid M., Muzammil S., Rasool M.H., Nisar M.A., Alvi R.F., Aslam M.A., Qamar M.U., et al. Antibiotic resistance: A rundown of a global crisis. Infect. Drug Resist. 2018;11:1645–1658. doi: 10.2147/IDR.S173867. - DOI - PMC - PubMed
    1. Tenover F.C. Mechanisms of Antimicrobial Resistance in Bacteria. Am. J. Med. 2006;34:S3–S10. doi: 10.1016/j.amjmed.2006.03.011. - DOI - PubMed

LinkOut - more resources